Establishment Labs Holdings Inc. $ESTA Shares Sold by CenterBook Partners LP

CenterBook Partners LP decreased its holdings in Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 75.0% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 55,616 shares of the company’s stock after selling 167,229 shares during the quarter. CenterBook Partners LP owned approximately 0.19% of Establishment Labs worth $4,053,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Quarry LP acquired a new position in shares of Establishment Labs in the third quarter worth about $34,000. State of Wyoming acquired a new stake in Establishment Labs during the third quarter valued at approximately $71,000. Osaic Holdings Inc. raised its stake in Establishment Labs by 900.0% during the second quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock valued at $85,000 after buying an additional 1,800 shares in the last quarter. Truist Financial Corp acquired a new stake in Establishment Labs during the fourth quarter valued at approximately $200,000. Finally, PharVision Advisers LLC acquired a new stake in Establishment Labs during the third quarter valued at approximately $203,000. Institutional investors and hedge funds own 72.91% of the company’s stock.

Establishment Labs Stock Performance

Shares of ESTA stock opened at $74.84 on Tuesday. Establishment Labs Holdings Inc. has a 12-month low of $33.35 and a 12-month high of $83.31. The firm has a market capitalization of $2.20 billion, a price-to-earnings ratio of -50.23 and a beta of 1.11. The business has a 50 day simple moving average of $66.79 and a 200 day simple moving average of $68.78. The company has a debt-to-equity ratio of 16.82, a current ratio of 2.96 and a quick ratio of 1.91.

Establishment Labs (NASDAQ:ESTA) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.10). Establishment Labs had a negative return on equity of 218.77% and a negative net margin of 19.05%.The business had revenue of $59.88 million during the quarter, compared to the consensus estimate of $57.40 million. During the same period last year, the company earned ($0.70) earnings per share. The business’s quarterly revenue was up 44.7% compared to the same quarter last year. On average, equities research analysts anticipate that Establishment Labs Holdings Inc. will post -1.07 EPS for the current year.

Analyst Ratings Changes

ESTA has been the topic of several research reports. TD Cowen restated a “buy” rating on shares of Establishment Labs in a research note on Monday. Stephens upped their price objective on Establishment Labs from $85.00 to $90.00 and gave the company an “overweight” rating in a research note on Wednesday, February 25th. Needham & Company LLC upped their price objective on Establishment Labs from $84.00 to $86.00 and gave the company a “buy” rating in a research note on Tuesday, February 24th. Weiss Ratings restated a “sell (e+)” rating on shares of Establishment Labs in a research note on Friday, March 27th. Finally, Wall Street Zen cut Establishment Labs from a “buy” rating to a “hold” rating in a research note on Saturday, March 28th. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Establishment Labs has an average rating of “Moderate Buy” and an average target price of $87.14.

Insider Transactions at Establishment Labs

In related news, Director Quiros Juan Jose Chacon sold 105,000 shares of the stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $75.42, for a total value of $7,919,100.00. Following the completion of the transaction, the director directly owned 927,504 shares of the company’s stock, valued at $69,952,351.68. This represents a 10.17% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Over the last three months, insiders sold 330,000 shares of company stock valued at $22,854,538. Corporate insiders own 9.99% of the company’s stock.

Establishment Labs Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.